Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — FY2021 Earnings Presentation
19 slides from Innate Pharma Sa Class A's earnings presentation, Mar 24, 2022
Slide 1: Full Year 2021 Results
Full Year 2021 Results March 24, 2022 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved.
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi, MD Joyson Karakunnel, MD, MSc, FACP Chief Executive Officer EVP, Chief Medical Officer Chairman of the Executive Board Yannis Morel, PhD Frédéric Lombard, MBA EVP, Business Development and SVP, Chief Financial Officer Product Portfolio Strategy (Q&A) 3
Slide 4: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Drive near-term Advance our Build sustainable value with innovative R&D business through Lacutamab pipeline partnerships 4
Slide 5: 2021 highlights: Significant progress across strategic priorities
2021 highlights: Significant progress across strategic priorities Lacutamab R&D pipeline Monalizumab Clinical progress: • Lacutamab – Phase 2 MF KIR3DL2- • IPH6101/SAR443579 (CD123 tri-specific ANKET) – • Monalizumab – Phase 3 NSCLC expressing TELLOMAK cohort advanced to Phase 1 trial start (Sanofi)
Slide 6: Our Robust Pipeline of Proprietary & Partnered Assets
Our Robust Pipeline of Proprietary & Partnered Assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status Sézary Syndrome TELLOMAK PHASE 2 (FDA FAST TRACK/EMA PRIME DESIGNATION) Preliminary Phase 2 data expected 2022 Early data presented Mycosis Fungoides TELLOMAK PHASE 2 Prelimina
Slide 7: TELLOMAK Phase 2 Study in Two CTCL Subtypes
LACUTAMAB TELLOMAK Phase 2 Study in Two CTCL Subtypes Potential for Sézary syndrome cohort to serve as pivotal trial Sézary Syndrome (N~60) Mycosis Fungoides (N~100) ≥ 2 prior systemic therapies ≥ 2 prior systemic therapies Cohort 1 Cohort 2# Cohort 3# All Comers* All comers, SS, must include KIR3DL
Slide 8: Encouraging Preliminary Results in KIR3DL2-Expressing MF Cohort of TELLOMAK Trial
LACUTAMAB Encouraging Preliminary Results in KIR3DL2-Expressing MF Cohort of TELLOMAK Trial Cohort 2 Overall response rate of ~35%* in advanced patient population with no current standard of care Cohort 3 Overall response rate of ~11%* KIR3DL2 non-expressors cohort did not progress to Stage 2 Cohort
Slide 9: Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas
LACUTAMAB Developing a New Standard of Care Across KIR3DL2- Expressing T-Cell Lymphomas Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-Cell Lymphoma (PTCL) Phase 2 TELLOMAK Trial Multi-trial Strategy Sezary Syndome Mycosis Fungoides From Relapsed to Frontline PTCL 80-200 patients 2,200-4,400 patients
Slide 10: Monalizumab: Phase 2 Data in NSCLC and HNSCC
MONALIZUMAB Monalizumab: Phase 2 Data in NSCLC and HNSCC 2021 data presentations provide rationale for further exploration in NSCLS and HNSCC COAST Phase 2 study of durvalumab alone or in combination with novel agents in Phase 2 study of monalizumab, cetuximab and durvalumab in first line treatment
Slide 11: Monalizumab: Early NSCLC
MONALIZUMAB Monalizumab: Early NSCLC Phase 3 program underway, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC NSCLC Phase 3 in unresectable, Stage III NSCLC STAGE I STAGE II STAGE III STAGE IV Phase 2 NeoCOAST* Phase 2 COAST* Stg I-IIIA NSCLC Unresect. Stg III NSCLC monali
Slide 12: Monalizumab: Head and Neck cancer
MONALIZUMAB Monalizumab: Head and Neck cancer Innate’s first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated SCCHN SCCHN 2L+ Phase 3 trial underway R/M SCCHN 1L 2L+ Phase 2 Cohort 3 Phase 2 Cohort 2 1L R/M SCCHN Post PDx R/R SCCHN monalizumab + durvalumab + cetuximab monal
Slide 13: ANKET: Innate's Proprietary NK Cell Engager Platform
ANKETTM ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46 is a versatile, fit-for- purpose technology that is creating Provides proliferation and activation signals
Slide 14: CD123 tri-specific SAR443579/IPH6101 Demonstrates Potent Antitumor Activity Against AML
ANKETTM CD123 tri-specific targeted SAR443579/IPH6101 Demonstrates Potent Antitumor Activity Against AML and Favorable Safety Profile SAR443579/IPH6101 kills AML cells resistant to ADCC SAR443579/IPH6101 induce CD123-expressing cell depletion in NHP with minor cytokine release ADCC-sensitive AML cel
Slide 15: Optimal Efficacy Requires All Arms in Tetra-specific ANKET
ANKETTM Optimal Efficacy Requires All Arms in Tetra-specific ANKET™ Demonstrate Superiority in Preclinical Model of Tumors Solid tumor models Disseminated tumor models Progressing towards IND enabling studies TAg: Tumor antigen *ADCC-enhanced mAb 15
Slide 16: 2021 Financial Highlights
2021 Financial Highlights Cash, cash equivalents and financial assets: €159.7m* as of December 31, 2021 • Sufficient to fund operations until mid 2023 Revenue/other income from continuing Operating expenses from continuing operations**: operations** : €24.7m €72.5m Licensing and collaborations: €12.
Slide 17: Key Newsflow Over the Next 2 Years
Key Newsflow Over the Next 2 Years 2 0 2 2 Data Readouts Clinical Progress • Monalizumab NeoCOAST Ph2 NSCLC (AstraZeneca) AACR • Monalizumab PACIFIC-9 NSCLC Phase 3 start (AstraZeneca) • Lacutamab Phase 2 MF data (preliminary) H2 • Monalizumab NeoCOAST-2 Phase 2 start (AstraZeneca) • Lacutamab Phase
Slide 18: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Lacutamab R&D pipeline Partnerships • TELLOMAK read-out with MF in • Advancing proprietary tetra- • Strong Phase 3 monalizumab 2021 and preliminary data for MF specific NK cell-targeted platform collaboration with AstraZeneca and SS in
Slide 19: Questions and Answers
Questions and Answers &S innate pharma